ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2020.102026
Abstract: Progress in cancer therapy changed the outcome of many patients and moved therapy from chemotherapy agents to targeted drugs. Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor)… read more here.
Keywords: chk1 pathway; atr chk1; leukemia; therapeutic target ... See more keywords
High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells
Sign Up to like & getrecommendations! Published in 2021 at "Blood Cancer Journal"
DOI: 10.1038/s41408-021-00531-2
Abstract: Mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia and primary myelofibrosis. To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we searched for small molecules that selectively inhibit… read more here.
Keywords: atr chk1; calr mutated; mutated cells; calr ... See more keywords